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journal homepage: www.j -bgm.comABSTRACTAngiotensin II type I receptor modulates
the migratory and invasive abilities of oral
squamous cell carcinoma (OSCC) via
MCP-1 signalingChun-Chieh Yu a, Chang-Han Chen a,ba Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung Taiwan
b Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital,
Chang Gung University College of Medicine, Kaohsiung, TaiwanBackground: Oral squamous cell carcinoma (OSCC) is associated with high rates of recurrence and mortality. Although
several well-known markers correlated with poor metastasis/prognosis in OSCC patients was reported, the molecular
mechanisms of OSCC development are still not clear. Here, we explored angiotensin II type I receptor (AT1R) and its-
elicited signaling pathway participates in the metastatic progression of OSCC.
Materials and Methods: The semi-quantitative-RT-PCR, Q-RT-PCR, western blot, and IHC approaches were used to evaluate
the mRNA/protein expressions of AT1R in paired OSCC specimens. Immunohistochemical (IHC) staining of AT1R expression
with clinic-patholgic characteristics was examined using univariate and multivariate analyses. Human oral cancer cell lines
with overexpressing-AT1R or AT1R-mediated siRNAs were generated by transfection. Transwell chamber, wound healing,
western blot, pharmacological inhibitors, and immunohistochemical assays were done to evaluate the signaling pathways
that were involved.
Results: We created a bioinformatics scheme consisting of integrating two gene expression profile datasets, including un-
pairwise OSCC, and secondary metastatic tumors vs. benign tumors. Among the novel targets identified, AT1R was up-
regulated in OSCC tissues and was associated with cancer metastasis. Furthermore, we employed two co-expression stra-
tegies to identify in which pathway AT1R was involved. By semi-quantitative-RT-PCR, Q-RT-PCR, Western blot and IHC
approaches, we found that AT1R was not only an indicator of poor survival, but also exhibits positive correlations with MCP-1
expression in OSCC specimens. In vitro study, AT1R-overexpressing transfectants could increase the motility of cells via up-
regulation MCP-1 expression. Conversely, the motility of oral cancer cells could be suppressed by knock-down endogenous
AT1R. These data indicated that AT1R promotes oral cancer metastasis via MCP-1 pathway.
Conclusions: These finding suggested that AT1R is not only an important prognostic factor but also a new therapeutic target
in the MCP-1 pathway for OSCC treatment.2214-0247/$36 Copyright ª 2013, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan LLC. All rights reserved.
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